Celldex Q3 net loss $38.3M ($0.81/shr); Phase 2 CSU enrollment complete, data by YE 2023

Celldex Therapeutics, Inc.

2023-Q3 EPS reported -$2.08 revenue$2,752,000

Net loss of $38.3M ($0.81 per share) vs $26.8M ($0.57) a year ago; revenue $1.5M.
Cash, equivalents and marketable securities $235.3M, sufficient to fund operations through 2025.
Phase 2 CSU study (n=208) enrollment complete; topline data expected by end of 2023.
Phase 1b prurigo nodularis data accepted for oral presentation at World Congress on Itch (Nov 5-7).
Phase 2 studies in CIndU, EoE ongoing; Phase 2 PN study planned for early 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Celldex Therapeutics, Inc. reported third quarter ended September 30, 2023 results: revenue $1.5 million.

Period: third quarter ended September 30, 2023
Revenue: $1.5 million
Result: reported results

Exact text from the filing

activities of $19.0 million for the three months ended September 30, 2023. At September 30, 2023, Celldex had 47.3 million shares outstanding. Revenues: Total revenue was $1.5 million in the third quarter of 2023 and $2.8 million for the nine months ended September 30, 2023, compared to $0.4 million and $0.7 million for the comparable periods in 2022. The

View on SEC.gov

Browse all earnings releases →

Celldex Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-006668

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.